Skip to main content
Clinical Trials/DRKS00033905
DRKS00033905
Not yet recruiting
未知

Prognostic impact of COronary Angiography in patients with acute ischemic Stroke and Troponin elevation - COAST-trial

niversität Heidelberg0 sites540 target enrollmentJune 7, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
I63
Sponsor
niversität Heidelberg
Enrollment
540
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 7, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversität Heidelberg

Eligibility Criteria

Inclusion Criteria

  • \[1] Written informed consent obtained from the patient or their guardian or written indication by the attending physician.
  • \[2] Age 40\-90 years.
  • \[3] Acute ischemic stroke with clinical and morphologic signs in the past 72 hours.
  • \[4] Increase in absolute troponin values depending on the troponin tests available in the respective study center according to the current ACS guidelines. This means either highly sensitive troponin assays (hs\-cTN) or conventional cTN assays with an increase and/or decrease above the 99th percentile of a healthy reference population (4th universal myocardial infarction definition).
  • \[5] One of these criteria must be met:
  • \- At least 3 cardiovascular risk factors from
  • o Obesity (BMI \>30kg/m2\)
  • o Arterial hypertension (treated with medication)
  • o Diabetes mellitus (treated with medication or diet)
  • o Dyslipoproteinemia (LDL \>150mg/dl or drug therapy)

Exclusion Criteria

  • \[1] Invasive exclusion of coronary heart disease (CHD) in the previous 12 months.
  • \[2] Acute ST\-segment myocardial infarction (STEMI), according to European ACS guideline (Byrne 2023 EHJ), New ST elevation at the J\-point in at least two contiguous leads: \- \=2\.5 mm in men \=2mm in men \=40 years, or \=1\.5 mm in women regardless of age in leads V2\-V3 and/or \=1 mm in the other leads (in the absence of left ventricular \[LV] hypertrophy or left bundle branch block \[LBBB]) documented in all uptake 12\-lead ECGs plus at the time of study inclusion.
  • \[3] History of grade III valvular heart disease.
  • \[4] Current endocarditis.
  • \[5] GOLD E stage COPD and/or COPD requiring long\-term oxygenation.
  • \[6] Pregnancy or breastfeeding.
  • \[7] Absolute contraindications for CA (e.g. hemorrhagic infarction, defined as parenchymal hematoma (PH) 1 and PH 2 according to Fiorelli (1999\), planned urgent surgery with absolute contraindication.
  • \[8] Persistent platelet count \< 50,000/µl at index hospitalization.
  • \[9] Severe acute infection, defined as C\-reactive protein \>100 g/dl and/or leukocytosis \>15,000/µl in combination with a clinical focus of infection.
  • \[10] Sepsis and septic shock according to the Sepsis 3 criteria.

Outcomes

Primary Outcomes

Not specified

Similar Trials